Agarose Bead Technologies (ABT)

Activities: Research & Development Analysis

Trending Articles

  1. Optimising RNA production for faster and cheaper pharmaceutical manufacturing RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
  2. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
  3. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  4. Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
  5. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Analysis

Agarose Bead Technologies triples its production capacity with major manufacturing expansion

Expansion of manufacturing facilities and increased production capacity are expected to meet the global demand for agarose resins that are used in processes supporting novel therapies
Subscribe now